Orlance, Inc., headquartered in Seattle, WA, is developing its MACH-1® platform to deliver nucleic acid vaccines and related therapies without cold chain restrictions.  Leveraging $9.6M in NIH SBIR funding, Orlance has developed the MACH-1 platform to intradermally deliver stable, powdered vaccines in a needle-free manner that minimizes dose size, eliminates cold chain requirements, and is poised to increase access and compliance.  The company’s executive team comprises significant immunology, vaccinology, biotech development, bioengineering, regulatory, and partnering experience and is well poised to bring its preclinical assets to IND and Phase 1 readiness in 2022.